Meta-Flux

Meta-Flux is a Dublin-based biotech startup building an 'AI Biologist' for pharmaceutical drug development. The platform uses feedback-loop knowledge graphs and multi-scale simulation models to process 20+ trillion biological data points across genes, proteins, metabolites, and patient phenotypes. It enables pharma teams to run rapid hypothesis-to-insight cycles, identify drug repurposing opportunities, flag off-target toxicity risks, and validate targets before costly preclinical work begins. Meta-Flux has demonstrated 97% diagnostic accuracy in sepsis disease modelling and ROC AUC of 0.994 in lung cancer biomarker identification. Founded in 2021 by Lee Sherlock (immunologist, Trinity College) and Brendan Martin (CTO), the company raised a $2.1M seed round in 2025 backed by executives from Pfizer, Merck, and Gilead Sciences.